These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 31595333)

  • 1. ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression.
    Papadimitriou MA; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3075-3087. PubMed ID: 31595333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
    Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
    Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients.
    Avgeris M; Tsilimantou A; Levis PK; Tokas T; Sideris DC; Stravodimos K; Ardavanis A; Scorilas A
    Br J Cancer; 2018 Dec; 119(12):1477-1486. PubMed ID: 30374124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer.
    Wang L; Zhao J; Yang C; Kuang R; Kazobinka G; Pang Z; Hou T
    Cell Physiol Biochem; 2018; 48(6):2364-2373. PubMed ID: 30114689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression.
    Tsikrika FD; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
    Genes Chromosomes Cancer; 2018 Mar; 57(3):150-161. PubMed ID: 29181884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer.
    Gaya JM; López-Martínez JM; Karni-Schmidt O; Bonal DM; Algaba F; Palou J; Villavicencio H; Benson MC; Cordon-Cardo C; Castillo-Martin M
    J Urol; 2015 Apr; 193(4):1144-50. PubMed ID: 25444981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.
    Gou Y; Ding W; Xu K; Wang H; Chen Z; Tan J; Xia G; Ding Q
    Int Urol Nephrol; 2015 Feb; 47(2):289-93. PubMed ID: 25388353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.
    Franco R; Zappavigna S; Gigantino V; Luce A; Cantile M; Cerrone M; Facchini G; Perdonà S; Pignata S; Di Lorenzo G; Chieffi S; Vitale G; De Sio M; Sgambato A; Botti G; Yousif AM; Novellino E; Grieco P; Caraglia M
    J Exp Clin Cancer Res; 2014 Jun; 33(1):48. PubMed ID: 24893613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
    Taber A; Park Y; Lelo A; Prip F; Xiao J; Berry DL; Chaldekas K; Jensen JB; Philips G; Kim JS; Harris BT; Dyrskjøt L; Waldman T
    Urol Oncol; 2021 Jul; 39(7):438.e1-438.e9. PubMed ID: 33712344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression.
    Karni-Schmidt O; Castillo-Martin M; Shen TH; Gladoun N; Domingo-Domenech J; Sanchez-Carbayo M; Li Y; Lowe S; Prives C; Cordon-Cardo C
    Am J Pathol; 2011 Mar; 178(3):1350-60. PubMed ID: 21356385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Ma JG; Li WP
    J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression.
    Piao XM; You C; Byun YJ; Kang HW; Noh J; Lee J; Lee HY; Kim K; Kim WT; Yun SJ; Lee SC; Kang K; Kim YJ
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladder.
    Hori S; Miyake M; Onishi S; Tatsumi Y; Morizawa Y; Nakai Y; Anai S; Tanaka N; Fujimoto K
    Oncol Rep; 2016 Oct; 36(4):2117-25. PubMed ID: 27573985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
    Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
    Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of cadherin-11 for subsequent recurrence and progression in non-muscle invasive bladder cancer.
    Chen MK; Chen ZJ; Xiao KH; Qin ZK; Ye YL; Wen WJ; Bian J; Xue KY; Zhou QZ; Guo WB; Zhou JH; Xia M; Li X; Liu CD
    Jpn J Clin Oncol; 2020 Apr; 50(4):456-464. PubMed ID: 31894237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.